Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Indian Journal of Surgery|November 8, 2012
A case of primary rhabdomyosarcoma of the breastVenkata Satya Suresh Attili, Hemant K Dadhich, Clementeena Ramarao, et al.
Oncotargets and Therapy|April 10, 2023
Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast CancerRevathi Badiginchala, Palanki Satya Dattatreya, Attili Venkata Satya Suresh, et al.
Journal of Cancer Research and Therapeutics|December 15, 2007
Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumorsVenkata Satya Suresh Attili, Rama C Chandra, G Anupama, et al.
Gastrointestinal Cancer Research : GCR|January 20, 2010
Influence of postoperative complications on relapse-free survival in gastrointestinal malignanciesV Satya Suresh Attili, Poonamalle P Bapsy, Chowdappa Ramachandra, et al.
European Journal of Cancer (Oxford, England : 1990)|October 8, 2016
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancerTimothy Price, Tae Won Kim, Jin Li, et al.
Cancer Biology & Therapy|October 7, 2020
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapyTimothy Price, Agnes Ang, Michael Boedigheimer, et al.
The Lancet. Oncology|April 18, 2014
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyTimothy J Price, Marc Peeters, Tae Won Kim, et al.
Hematological Oncology|November 15, 2019
Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trialIrina V Poddubnaya, Sergey M Alekseev, Kamil D Kaplanov, et al.
Pageof 2